MORRISTOWN, N.J.--(BUSINESS WIRE)--Add after 3rd bullet point in release: Mark Scheideler, Founder, HumanFirst Therapeutics. Also adding multimedia.
The corrected release reads:
RXC INTERNATIONAL TO LEAD GENE THERAPY PANEL AT NEWYORKBIO ANNUAL CONFERENCE MAY 11 - 12, 2016
RxC International today announced that it has been selected by NewYorkBIO, New York State’s life science trade association, to lead a panel on gene therapy at its annual conference in New York City, May 11 - 12, 2016. The panel will be led by RxC International Senior Partner Richard Tinsley.
“We are excited to bring a diverse group of thought leaders together to explore the fast-emerging gene therapy segment of the life sciences industry,” said Subbarao Jayanthi, managing partner of RxC International.
RxC International Senior Partner Richard Tinsley said, “Although there are only four gene therapy products approved across the major developed markets – North America, the EU, and Japan – there are nearly 1,000 active gene therapy programs in development across a wide range of therapy areas and disease states. Gene therapy programs face a range of unique R&D, commercialization, funding, legal and ethical issues. Our panel will explore some of the hurdles faced by life science leaders working with this promising therapeutic class.”
The RxC International gene therapy panel members will include:
- Sean Ainsworth, CEO, RetroSense
- Constance Bagley, Senior Research Scholar at Yale Law School, consultant, and author
- Jim Dentzer, Chief Financial and Chief Administrative Officer at Curis
- Mark Scheideler, Founder, HumanFirst Therapeutics
“We are pleased to have RxC International’s participation at the conference given its focus as an organization on this topic and the growing interest across the industry in this therapy area,” said NewYorkBIO Executive Director Nathan Tinker.
About New York Biotechnology Association, Inc.
New York Biotechnology Association, Inc. (NewYorkBIO) supports the development and growth of New York State's life science industry and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. For over 25 years, NewYorkBIO and its 250+ member companies have been at the forefront of developing, nurturing, and expanding New York’s life science industry. For more information about NewYorkBIO and the conference, see: www.newyorkbio.org.
About RxC International
RxC International is a premier life sciences management consulting firm. The RxC team collaborates with clients to identify and develop growth opportunities. RxC leverages consulting partners and advisers to combine strategic and operational expertise to bring multiple perspectives to every engagement. RxC has deep expertise in corporate strategy, new product planning and commercial excellence.
RxC International clients include global pharmaceutical and biotechnology companies as well as other specialty life sciences companies such as vaccine, biosimilar, diagnostic, and medical device companies. RxC has offices in New Jersey, Massachusetts, and California. Additional information about RxC International can be found at www.rxcinternational.com.
